Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: An index of atherogenicity?

Atherosclerosis

Volumn 168, Issue 1, 2003, Pages 107-113

  Badiou, S ^a   Merle De Boever, C ^a   Dupuy, A M ^a   Baillat, V ^a   Cristol, J P ^a   Reynes, J ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Apolipoprotein CIII; Atherogenic risk; HIV dyslipidemia; Hypertriglyceridemia; Lopinavir ritonavir; Small dense LDL

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; PREVALENCE; PRIORITY JOURNAL; TIME;

EID: 0038065609     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00058-3     Document Type: Article

References (33)

1. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353:1999;2093-2099.
2. Behrens G., Dejam A., Schmidt H., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 13:1999;F63-F70.
3. Safrin S., Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 13:1999;2493-2505.
4. Periard D., Teleni A., Sudre P., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 100:1999;700-705.
5. Acevedo M., Sprecher D.L., Calabrese L., et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. Atherosclerosis. 163:2002;349-354.
6. Seminari E., Pan A., Voltini G., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 162:2002;433-438.
7. Chapman J., Bruckert E. The atherogenic role of triglycerides and small dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis. Suppl. 124:1996;21-28.
8. Bonnet E., Ruidavets J.B., Tuech J., et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J. Clin. Endocrinol. Metab. 86:2001;296-302.
9. Stein J.H., Klein M.A., Bellehumeur J.L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 104:2001;257-262.
10. Lamarche B., Lemieux I., Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 25:1999;199-211.
11. St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104:2001;2295-2299.
12. Murphy R.L., Brun S., Hicks C., et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. AIDS. 15:2001;1-9.
13. Benson C.A., Deeks S.G., Brun S.C., et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor - experienced patients. J. Infect. Dis. 185:(5):2002;599-607.
14. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1-19.
15. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol. 128:1986;155-170.
16. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta. 665:1981;408-419.
17. Wall JL, David M, Fichtenbaum CJ. The risk of Ischemic Cardiovascular Disease Is Significant in Persons with HIV infection. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Feb 2002 [Abstract 695-T].
18. Klein D., Hurley L.B., Quesenberry C.P. Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30:2002;471-477.
19. Maggi P., Serio G., Epifani G., et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 14:(16):2000;F123-128.
20. Mercie P, Thiebault R, Lavignolle V et al. and the Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 55-63.
21. Leport C, Saves M, Ducimetiere P et al. Coronary Heart Disease Risk (CHD) in French HIV-Infected Men Started on a Protease Inhibitor (PI)-Containing Regimen Compared to the General Population. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Feb 2002 [Abstract 697T].
22. Holmberg S.D., Moorman A.C., Williamson J.M., et al. HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 360:2002;1747-1748.
23. Depairon M., Chessex S., Sudre P., et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS. 15:2001;329-334.
24. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74:1992;1045-1052.
25. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am. J. Cardiol. 88:(12A):2001;9N-13.
26. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 358:2001;2026-2033.
27. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J. 19:(Suppl. A):1998;A24-A30.
28. Schmitz M., Michl G.M., Walli R., et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J. Acquir. Immune Defic. Syndr. 26:2001;225-235.
29. Packard C.J., Sheperd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17:1997;3542-3556.
30. Guerin M., Legoff W., Lassel T.S., Van Tol A., Steiner G., Chapman M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;282-288.
31. Fauvel J., Bonnet E., Ruidavts J.B., et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 15:2001;2397-2406.
32. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16:1996;763-772.
33. Lemieux I., Laperrière L., Dzavik V., Tremblay G., Bourgeois J., Despres J.P. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis. 162:2002;363-371.